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Reply
We thank Fisman et all for calling our attention to their interesting study examining the effects of maximum supine bicycle exercise on left ventricular function in endurance-trained athletes. Their study differs substantially from our study2 in both the duration and intensity of exercise as well as in the timing of postexercise echocardiographic study, since their athletes were studied at peak exercise and ours were studied an average of 11 + 5 minutes after finishing exercise. Fisman et al describe the occurrence of "regional wall motion abnormalities" in eight of their 22 athletes. However, when these abnormalities are further characterized, only one subject showed a true segmental wall motion abnormality with dyskinesia of the anterior wall. The other seven patients had an unchanged (three) or symmetrically (four) hypokinetic wall motion pattern. Only the patient with dyskinesia can truly be diagnosed as having a regional abnormality. Furthermore, although their qualitative examination resulted in diagnoses of symmetric hypokinesia in four athletes plus dyskinesia in one athlete, the quantitative estimates of ejection fraction show a reduced ejection fraction in only two subjects. Thus, the quantitative and qualitative analyses of left ventricular function do not agree in at least three cases. This discrepancy is not explained further in their article.
Fisman et al's finding of an abnormal ejection fraction response at peak exercise in 41 % of athletes is quite interesting. Our results are not comparable because our subjects were studied after a significant recovery period; we interpreted our data as showing a reduction in ejection fraction after prolonged exercise rather than as addressing the issue of left ventricular function during exercise.
We agree that loading conditions are an extremely important determinant of ejection phase indexes such as ejection fraction. Preload was probably reduced in our subjects with a reduction, albeit not statistically significant, in left ventricular diastolic volume from 147 to 140 ml. Because this was accompanied by an average weight loss of 1.6 kg, it was most likely due to dehydration.
We agree with Fisman et al's point that hypertrophic left ventricular walls could respond differently than walls of normal thickness. In contradistinction to patients with pathological hypertrophy, increased myocardial stiffness and increased connective tissue content are not seen in athletes, who generally have physiological hypertrophy. In previous studies, we noted the prevalence of left ventricular hypertrophy in similar triathlete populations to be only 53-62%3 with an average wall thickness of 1.0±0.4 cm.4 Thus, the hypertrophy, when seen, is fairly mild, especially in comparison to that associated with cardiac disease states in which the abnormalities noted by Fisman et al were described. Nevertheless, our study design does not allow us to address the issue of whether our findings can be extrapolated to healthy sedentary subjects. Pamela S. Douglas, MD Jean Woolard, CCPT Beth Israel Hospital Cardiovascular Division Boston, Mass.
Increased Susceptibility to Reentrant Arrhythmias by Flecainide
We appreciate the interesting comments of Dr. El-Sherif1 on our article.2 Indeed, proarrhythmic mechanisms based on reentrant rhythms are not yet well understood. The aim of our study was to attempt to better understand this difficult problem. We did not try to explain the proarrhythmic effect of flecainide by the two exceptions in our series in which a tachycardia could be induced both during control and flecainide. As Dr. El-Sherif emphasizes, ventricular tachycardia was slower in both cases after flecainide compared with control, thus confirming once more that flecainide is an antiarrhythmic drug as well as a proarrhythmic one. However, induction of a previously unrecognized reentrant arrhythmia, or transformation of nonsustained tachycardia into sustained reentrant tachycardia, as occurred in 70% of the hearts, can certainly be called a proarrhythmic effect. The most obvious conclusion of our study was that flecainide modified the electrophysiological matrix, creating the substrate for reentry. Depression of active membrane properties after flecainide clearly enhanced the occurrence of unidirectional conduction block. How close these observations may apply to the clinical situation will only be understood after careful clinical studies addressing the same issue. Experimental models of reentry are created to advance our knowledge about specific points of this complex mechanism of arrhythmia. To pretend that only those models perfectly mimicking the clinical situation are valuable would have led the scientific community to ignore the initial description of reentry by Mayer3 in artificially created rings in jellyfish. Dr. El-Sherif suggests that one possible mechanism "not yet demonstrated" for proarrhythmia would be the induction of faster reentrant circuits, which could easily degenerate into ventricular fibrillation; we have previously reported this kind of proarrhythmia in a model of anatomically determined reentry. 
